Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease

Current Cardiology Reports

Volumn 11, Issue 6, 2009, Pages 468-475

  Cromwell, William C ^a   Barringer, Thomas A ^b  

^a Division of Atherosclerosis and Lipoprotein Disorders   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE; OUTCOME ASSESSMENT; PREVALENCE; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; RISK ASSESSMENT;

EID: 72849117236     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0067-z     Document Type: Review

References (48)

1. L. Nielsen 1996 Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis Atherosclerosis 123 1 15 10.1016/0021-9150(96) 05802-9 1:CAS:528:DyaK28XjtlSmtLk%3D 8782833 (Pubitemid 26175065)
2. I. Tabas K.J. Williams J. Boren 2007 Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 1832 1844 10.1161/CIRCULATIONAHA.106.676890 1:CAS:528:DC%2BD2sXhtFersLnL 17938300 (Pubitemid 350287108)
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report [no authors listed]. Circulation 2002, 106:3143-3421.
4. S.M. Grundy J.I. Cleeman C.N. Merz, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516 (Pubitemid 38924592)
5. R.A. Hayward T.P. Hofer S. Vijan 2006 Narrative Review: Lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem Ann Intern Med 145 520 530 17015870
6. A.D. Sniderman C.D. Furberg A. Keech, et al. 2003 Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 777 780 10.1016/S0140-6736(03)12663-3 1:CAS:528:DC%2BD3sXhs1WktL4%3D 12620753 (Pubitemid 36293636)
7. P.J. Barter C.M. Ballantyne R. Carmena, et al. 2006 Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 247 258 10.1111/j.1365-2796.2006.01616.x 1:CAS:528:DC%2BD28XjslCmtLY%3D 16476102
8. A.M. Gotto Jr E. Whitney E.A. Stein, et al. 2000 Relation between baseline and on-treatment Lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 477 484 1:CAS:528:DC%2BD3cXhtlajtr4%3D 10662743
9. R.J. Simes I.C. Marschner D. Hunt, et al. 2002 Relationship between lipid levels and clinical outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105 1162 1169 10.1161/hc1002.105136 1:CAS:528:DC%2BD38XivFarur4%3D 11889008 (Pubitemid 34225815)
10. J.E. van Lennep H.T. Westerveld H.W. van Lennep, et al. 2000 Apolipoprotein concentrations during treatment and recurrent coronary artery disease events Arterioscler Thromb Vasc Biol 20 2408 2413 11073845
11. A. Sniderman H. Vu K. Cianflone 1991 Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels Atherosclerosis 89 109 116 10.1016/0021-9150(91)90050-D 1:CAS:528: DyaK38XjvFWnsQ%3D%3D 1793438
12. W.T. Garvey S. Kwon D. Zheng, et al. 2003 Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 453 462 10.2337/diabetes.52.2.453 1:CAS:528:DC%2BD3sXhtFansLw%3D 12540621 (Pubitemid 36173203)
13. E.J. Jeyarajah W.C. Cromwell J.D. Otvos 2006 Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy Clin Lab Med 26 847 870 10.1016/j.cll.2006.07.006 17110242 (Pubitemid 44716510)
14. J.D. Otvos E.J. Jeyarajah W.C. Cromwell 2002 Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 22i 29i 10.1016/S0002-9149(02) 02632-2 1:CAS:528:DC%2BD38XptFarsb0%3D 12419478
15. W.C. Cromwell J.D. Otvos 2006 Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl Am J Cardiol 98 1599 1602 10.1016/j.amjcard.2006.07.036 1:CAS:528:DC%2BD28Xht1Kks7bM 17145217 (Pubitemid 44827965)
16. W.C. Cromwell J.D. Otvos M.J. Keyes, et al. 2007 LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management J Clin Lipidol 1 583 592 10.1016/j.jacl.2007.10. 001 19657464 (Pubitemid 350215511)
17. A.D. Sniderman 2008 Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 36 42 10.1016/j.jacl.2007.12.006 (Pubitemid 351250867)
18. P. Cremer D. Nagel H. Mann, et al. 1997 Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men Atherosclerosis 129 221 230 10.1016/S0021-9150(96)06030-3 1:CAS:528:DyaK2sXislOrsrc%3D 9105565 (Pubitemid 27135324)
19. G. Walldius I. Jungner I. Holme, et al. 2001 High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2026 2033 10.1016/S0140-6736(01)07098-2 1:CAS:528:DC%2BD38XhsFSn 11755609 (Pubitemid 34084825)
20. L.A. Simons J. Simons Y. Friedlander J. McCallum 2002 Risk factors for acute myocardial infarction in the elderly (the Dubbo study) Am J Cardiol 89 69 72 10.1016/S0002-9149(01)02168-3 11779528 (Pubitemid 34066592)
21. P.J. Talmud E. Hawe G.J. Miller S.E. Humphries 2002 Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men Arterioscler Thromb Vasc Biol 22 1918 1923 10.1161/01.ATV.0000035521.22199.C7 1:CAS:528:DC%2BD38Xot1OitLY%3D 12426225 (Pubitemid 35315782)
22. R. Jiang M.B. Schulze T. Li, et al. 2004 Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 27 1991 1997 10.2337/diacare.27.8.1991 1:CAS:528:DC%2BD2cXntVygt7c%3D 15277429 (Pubitemid 38989244)
23. I. Shai E.B. Rimm S.E. Hankinson, et al. 2004 Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines Circulation 110 2824 2830 10.1161/01.CIR.0000146339.57154.9B 15492318 (Pubitemid 39473604)
24. T. Pischon C.J. Girman F.M. Sacks, et al. 2005 Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 112 3375 3383 10.1161/CIRCULATIONAHA.104.532499 1:CAS:528:DC%2BD2MXht1Cqt7%2FK 16316964 (Pubitemid 43739551)
25. P.M. Ridker N. Rifai N.R. Cook, et al. 2005 Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 326 333 10.1001/jama.294.3.326 1:CAS:528:DC%2BD2MXmtlGks78%3D 16030277 (Pubitemid 41043776)
26. M. Benn B.G. Nordestgaard G.B. Jensen A. Tybjaerg-Hansen 2007 Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study Arterioscler Thromb Vasc Biol 27 661 670 10.1161/01.ATV.0000255580.73689.8e 1:CAS:528:DC%2BD2sXhsVSit7o%3D 17170368 (Pubitemid 46263415)
27. E. Ingelsson E.J. Schaefer J.H. Contois, et al. 2007 Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 776 785 10.1001/jama.298.7.776 1:CAS:528:DC%2BD2sXpt1enurg%3D 17699011 (Pubitemid 47263160)
28. G.J. Blake J.D. Otvos N. Rifai, et al. 2002 Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women Circulation 106 1930 1937 10.1161/01.CIR.0000033222.75187.B9 1:CAS:528:DC%2BD38XnsVartrw%3D 12370215 (Pubitemid 35176297)
29. L. Kuller A. Arnold R. Tracy, et al. 2002 Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study Arterioscler Thromb Vasc Biol 22 1175 1180 10.1161/01.ATV.0000022015.97341.3A 1:CAS:528:DC%2BD38XlsFSgsL0%3D 12117734 (Pubitemid 34764870)
30. K. El Harchaoui W.A. van der Steeg E.S. Stroes, et al. 2007 Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 49 547 553 10.1016/j.jacc.2006.09.043 17276177 (Pubitemid 46177441)
31. S. Mora M. Szklo J.D. Otvos, et al. 2007 LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 192 211 217 10.1016/j.atherosclerosis. 2006.05.007 1:CAS:528:DC%2BD2sXksV2ruro%3D 16765964 (Pubitemid 46602300)
32. S. Mora J.D. Otvos N. Rifai, et al. 2009 Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 931 919 10.1161/CIRCULATIONAHA.108.816181 1:CAS:528:DC%2BD1MXhvFentr8%3D 19204302
33. G. Ruotolo C.-G. Ericsson C. Tettamanti, et al. 1998 Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) J Am Coll Cardiol 32 1648 1656 10.1016/S0735-1097(98)00442-2 1:CAS:528:DyaK1cXnvVymsbo%3D 9822092 (Pubitemid 28545204)
34. J. Vakkilainen G. Steiner J.C. Ansquer, et al. 2003 Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS) Circulation 107 1733 1737 10.1161/01.CIR.0000057982.50167.6E 12665498 (Pubitemid 36418352)
35. R.S. Rosenson J.D. Otvos D.S. Freedman 2002 Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am J Cardiol 90 89 94 10.1016/S0002-9149(02)02427-X 1:CAS:528:DC%2BD38XltFSru74%3D 12106834 (Pubitemid 34775113)
36. J.D. Otvos D. Collins D.S. Freedman, et al. 2006 Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 113 1556 1563 10.1161/CIRCULATIONAHA. 105.565135 1:CAS:528:DC%2BD28XisFygs70%3D 16534013 (Pubitemid 43739414)
37. J. Genest J. Frohlich G. Fodor R. McPherson 2003 Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update CMAJ 169 921 924 14581310
38. J.D. Brunzell M. Davidson C.D. Furberg, et al. 2008 Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 1512 1524 10.1016/j.jacc.2008.02.034 18402913
39. J.H. Contois J.P. McConnell A.A. Sethi, et al. 2009 Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 407 419 10.1373/clinchem.2008.118356 1:CAS:528:DC%2BD1MXivFaqsb0%3D 19168552
40. S. Kathiresan J.D. Otvos L.M. Sullivan, et al. 2006 Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 20 29 10.1161/CIRCULATIONAHA.105.567107 1:CAS:528:DC%2BD2MXhtlCrtbnL 16380547 (Pubitemid 43958484)
41. A.D. Sniderman A.C. St-Pierre B. Cantin, et al. 2003 Concordance/ discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 1173 1177 10.1016/S0002-9149(03)00262-5 1:CAS:528:DC%2BD3sXjs1Cqs7c%3D 12745098 (Pubitemid 36561379)
42. B. KK K. RM 2002 Metabolic origins and clinical significance of LDL heterogeneity J Lipid Res 43 1363 1379 10.1194/jlr.R200004-JLR200
43. B.J. Kim S.T. Hwang K.C. Sung, et al. 2005 Comparison of the relationships between serum apolipoprotein B and serum lipid distributions Clin Chem 51 2257 2263 10.1373/clinchem.2005.052738 1:CAS:528:DC%2BD2MXht1yks7fJ 16214827 (Pubitemid 41692568)
44. E.A. Stein A. Sniderman P. Laskarzewski 2005 Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 96 36K 43K 10.1016/j.amjcard.2005.08.006 1:CAS:528:DC%2BD2MXhtlGgs7vI 16291013 (Pubitemid 41598111)
45. A.D. Sniderman G.R. Dagenais B. Cantin, et al. 2001 High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol Am J Cardiol 87 792 793 10.1016/S0002-9149(00)01508-3 1:CAS:528:DC%2BD3MXhvVamsLY%3D 11249908 (Pubitemid 32209103)
46. J.D. Otvos 2009 Our own inconvenient truth: LDL cholesterol is a flawed measure of LDL. Time to acknowledge the problem and its clinical implications The Fats of Life 23 16 20
47. Cromwell WC, Bays HE, Toth PP: Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy. In Markers in Cardiology: A Case-Oriented Approach. Edited by Adams JE, Apple F, Jaffe AS. London: Blackstone Press; 2007:217-250.
48. K.C. Maki J.M. McKenney M.S. Reeves, et al. 2008 Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia Am J Cardiol 102 429 433 10.1016/j.amjcard.2008.03.078 1:CAS:528:DC%2BD1cXpsVagsrs%3D 18678300